Fiche centre
University of North Carolina
Chapel Hill — United States
Essais liés11clinical trials
VilleChapel Hilllocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07659795
Essais cliniques associés
11| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| OPTIMIZER® Integra CCM-D System (Treatment Arm) | Maladie coronarienne | Non applicable | NCT05855135 | INTEGRA-D — Assessment of Combined CCM and ICD Device in HFrEF | ACTIVE_NOT_RECRUITING |
| AFSW Guided DOAC | Accident vasculaire cérébral | Phase 3 | NCT05836987 | REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | RECRUITING |
| IVC Sensor | Insuffisance cardiaque | Non applicable | NCT07574593 | NORM-HF Pivotal Study | RECRUITING |
| VS-7375 | Cancer | Phase 2 | NCT07659795 | TARGET-D 203 — A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | RECRUITING |
| Pitolisant Oral Tablet | Myopathies | Phase 2 | NCT04886518 | Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 | COMPLETED |
| Descartes-08 | Myopathies | Phase 2 | NCT07391605 | Descartes-08 in Autoantibody Myositis | RECRUITING |
| EXPLORE-MG2 — Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | Myasthénie | À vérifier | NCT06002945 | EXPLORE-MG2 — Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | COMPLETED |
| Anti-hypertensive therapy | Hypertension | Phase 4 | NCT02299414 | Chronic Hypertension and Pregnancy (CHAP) Project | COMPLETED |
| Renal Denervation (Symplicity Spyral™) | Hypertension | Non applicable | NCT05198674 | SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN | ACTIVE_NOT_RECRUITING |
| Descartes-08 | Myasthénie | Phase 2 | NCT04146051 | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | ACTIVE_NOT_RECRUITING |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |